title: Two-year treatment outcomes of patients enrolled in India's national first-line antiretroviral therapy programme.
abstract: BACKGROUND
  We aimed to analyse treatment outcomes of patients receiving first-line antiretroviral therapy (ART) through the national AIDS control programme of India.
  
  
  METHODS
  Using routinely collected programme data, we analysed mortality, CD4 evolution and adherence outcomes over a 2-year period in 972 patients who received first-line ART between 1 October 2004 and 31 January 2005 at 3 government ART centres. Cox regression analysis was used to identify independent predictors of mortality.
  
  
  RESULTS
  Of the 972 patients (median age 35 years, 66% men), 71% received the stavudinellamivudine/nevirapine regimen. The median CD4 count of enrolled patients was 119 cells/cmm (interquartile range [IQR] 50-200 cells/ cmm) at treatment initiation; 44% had baseline CD4 count <100 cells/cmm. Of the 927 patients for whom treatment outcomes were available, 71% were alive after 2 years of treatment. The median increase in CD4 count was 1 42 cells/ cmm (IQR 57-750 cells/cmm; n=616) at 6 months and 184 cells/cmm (IQR 102-299 cells/cmm; n=582) at 12 months after treatment. Over 2 years, 124 patients (13%) died; the majority of deaths (68%) occurred within the first 6 months of treatment. Those with baseline CD4 count <50 cells/cmm were significantly more likely to die (adjusted hazard ratio 2.5, 95% confidence interval 1.3-3.2) compared with patients who had baseline CD4 count >50 cells/cmm. Over the 2-year period, 323 patients (35%) missed picking up their monthly drugs at least once and 147 patients (16%) were lost to follow up.
  
  
  CONCLUSIONS
  Survival rates of HIV-infected patients on first-line ART in India were comparable with those from other resource-limited countries. Most deaths occurred early and among patients who had advanced disease. Earlier initiation of HIV treatment and improving long term treatment adherence are key priorities for India's ART programme.
authors.affiliation: National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
authors.forename: Damodar
authors.initials: D
authors.lastname: Bachani
authors.forename: Renu
authors.initials: R
authors.lastname: Garg
authors.forename: Bharat B
authors.initials: BB
authors.lastname: Rewari
authors.forename: Lea
authors.initials: L
authors.lastname: Hegg
authors.forename: Sikhamani
authors.initials: S
authors.lastname: Rajasekaran
authors.forename: Alaka
authors.initials: A
authors.lastname: Deshpande
authors.forename: K V
authors.initials: KV
authors.lastname: Emmanuel
authors.forename: Polin
authors.initials: P
authors.lastname: Chan
authors.forename: K Sujatha
authors.initials: KS
authors.lastname: Rao
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents